JP2022141670A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022141670A5 JP2022141670A5 JP2022103103A JP2022103103A JP2022141670A5 JP 2022141670 A5 JP2022141670 A5 JP 2022141670A5 JP 2022103103 A JP2022103103 A JP 2022103103A JP 2022103103 A JP2022103103 A JP 2022103103A JP 2022141670 A5 JP2022141670 A5 JP 2022141670A5
- Authority
- JP
- Japan
- Prior art keywords
- aav vector
- cell
- pharmaceutical composition
- subject
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024112812A JP2024156706A (ja) | 2015-10-28 | 2024-07-12 | 遺伝子治療 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1519086.1 | 2015-10-28 | ||
| GBGB1519086.1A GB201519086D0 (en) | 2015-10-28 | 2015-10-28 | Gene Therapy |
| JP2018541571A JP7126944B2 (ja) | 2015-10-28 | 2016-10-27 | 遺伝子治療 |
| PCT/GB2016/053343 WO2017072515A1 (en) | 2015-10-28 | 2016-10-27 | Gene therapy |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541571A Division JP7126944B2 (ja) | 2015-10-28 | 2016-10-27 | 遺伝子治療 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024112812A Division JP2024156706A (ja) | 2015-10-28 | 2024-07-12 | 遺伝子治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022141670A JP2022141670A (ja) | 2022-09-29 |
| JP2022141670A5 true JP2022141670A5 (https=) | 2022-10-07 |
Family
ID=55130363
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541571A Active JP7126944B2 (ja) | 2015-10-28 | 2016-10-27 | 遺伝子治療 |
| JP2022103103A Pending JP2022141670A (ja) | 2015-10-28 | 2022-06-28 | 遺伝子治療 |
| JP2024112812A Pending JP2024156706A (ja) | 2015-10-28 | 2024-07-12 | 遺伝子治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541571A Active JP7126944B2 (ja) | 2015-10-28 | 2016-10-27 | 遺伝子治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024112812A Pending JP2024156706A (ja) | 2015-10-28 | 2024-07-12 | 遺伝子治療 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20190255193A1 (https=) |
| EP (3) | EP3360890B1 (https=) |
| JP (3) | JP7126944B2 (https=) |
| KR (1) | KR102922606B1 (https=) |
| CN (4) | CN117343960A (https=) |
| AU (3) | AU2016344523B2 (https=) |
| CA (1) | CA3002125A1 (https=) |
| DK (2) | DK3262066T4 (https=) |
| ES (2) | ES2828050T3 (https=) |
| GB (1) | GB201519086D0 (https=) |
| HK (1) | HK1248723B (https=) |
| IL (3) | IL304084B2 (https=) |
| MX (1) | MX366343B (https=) |
| NO (1) | NO3262066T3 (https=) |
| PL (2) | PL3360890T3 (https=) |
| RU (1) | RU2740038C2 (https=) |
| SG (1) | SG11201802934WA (https=) |
| WO (1) | WO2017072515A1 (https=) |
| ZA (1) | ZA201802462B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108291216B (zh) | 2015-09-24 | 2022-09-16 | 宾夕法尼亚州大学信托人 | 用于治疗补体介导的疾病的组合物和方法 |
| GB201519086D0 (en) * | 2015-10-28 | 2015-12-09 | Syncona Partners Llp | Gene Therapy |
| JP7046828B2 (ja) | 2016-04-15 | 2022-04-04 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 滲出型加齢性黄斑変性の治療のための組成物 |
| GB201608046D0 (en) * | 2016-05-09 | 2016-06-22 | Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The | Treatment of complement-mediated disorders |
| KR20200036912A (ko) * | 2017-07-31 | 2020-04-07 | 리플렉션 바이오테크놀러지스 리미티드 | 안과 질환을 위한 세포 모델 및 치료요법 |
| CN111788311A (zh) * | 2017-10-20 | 2020-10-16 | 双子治疗公司 | 用于治疗年龄相关性黄斑变性的组合物和方法 |
| US12558434B2 (en) | 2018-02-20 | 2026-02-24 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| WO2020077091A1 (en) * | 2018-10-10 | 2020-04-16 | Wisconsin Alumni Research Foundation | Kir 7.1 gene therapy vectors and methods of using the same |
| CA3117551A1 (en) * | 2018-10-23 | 2020-04-30 | Gemini Therapeutics Inc. | Compositions and methods for treating age-related macular degeneration and other diseases |
| GB201821089D0 (en) * | 2018-12-21 | 2019-02-06 | Gyroscope Therapeutics Ltd | Codon-optimised complement factor I |
| GB201821082D0 (en) * | 2018-12-21 | 2019-02-06 | Gyroscope Therapeutics Ltd | Combination of complement factors i and h, and vector encoding thereof |
| EP4667578A3 (en) * | 2019-04-03 | 2026-04-01 | REGENXBIO Inc. | Gene therapy for eye pathologies |
| EP4028025A4 (en) * | 2019-09-09 | 2023-07-19 | University of Pittsburgh - of the Commonwealth System of Higher Education | METHODS OF RESTORING LYSOSOMAL FUNCTION OF RETINAL PIGMENT EPITHELIAL CELLS BY TFEB ACTIVATION |
| AU2021293174A1 (en) | 2020-06-14 | 2023-01-19 | Vertex Pharmaceuticals Incorporated | Complement Factor I-related compositions and methods |
| GB202009741D0 (en) | 2020-06-25 | 2020-08-12 | Freeline Therapeutics Ltd | Polynucleotide |
| IL301131A (en) * | 2020-09-09 | 2023-05-01 | Homology Medicines Inc | Vector antibodies and their uses |
| US20230390296A1 (en) | 2020-10-30 | 2023-12-07 | Keio University | Novel treatment and prevention of sarcopenia-related diseases |
| GB202018320D0 (en) * | 2020-11-20 | 2021-01-06 | Univ Newcastle | Methods of producing recombinant complement proteins |
| WO2023079301A1 (en) | 2021-11-04 | 2023-05-11 | Freeline Therapeutics Limited | Assays using mutant complement factor i variants with decreased activity |
| JPWO2023145735A1 (https=) | 2022-01-25 | 2023-08-03 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| US6759237B1 (en) | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
| GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| RU2005138368A (ru) * | 2003-06-10 | 2006-07-27 | ЭнЭсДЖЕНЕ А/С (DK) | Улучшенная секреция нейбластина |
| EP2357254A1 (en) | 2005-02-14 | 2011-08-17 | University of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of age-related macular degeneration |
| EP2433642B1 (en) * | 2005-10-21 | 2016-12-07 | Catalyst Biosciences, Inc. | Modified proteases that inhibit complement activation |
| WO2007149567A2 (en) | 2006-06-21 | 2007-12-27 | Musc Foundation For Research Development | Targeting complement factor h for treatment of diseases |
| CN101657097A (zh) * | 2007-03-01 | 2010-02-24 | 先进视觉疗法公司 | 以炎症为特征的疾病的治疗 |
| CA2678774A1 (en) * | 2007-03-01 | 2008-09-04 | Advanced Vision Therapies, Inc. | Treatment of diseases characterized by inflammation |
| DK2191001T3 (en) | 2007-04-09 | 2016-09-19 | Univ Florida | RAAV VECTOR COMPOSITIONS WITH TYROSIN MODIFIED CAPSIDE PROTEINS AND PROCEDURES FOR USE THEREOF |
| GB0816702D0 (en) * | 2008-09-12 | 2008-10-22 | Trinity College Dublin | Complement proteins |
| GB0904427D0 (en) * | 2009-03-13 | 2009-04-29 | Lachmann Peter | Treatment of diseases related to hyperactivity of the complement system |
| TWI775096B (zh) * | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| AU2014209350B8 (en) * | 2013-01-23 | 2019-04-18 | Department Of Veterans Affairs (Us) | Targeting constructs based on natural antibodies and uses thereof |
| US20140234275A1 (en) * | 2013-02-15 | 2014-08-21 | Jason Williams | Method for treating als via the increased production of factor h |
| CN105682674A (zh) * | 2013-04-17 | 2016-06-15 | 建新公司 | 用于治疗和预防黄斑变性的组合物和方法 |
| EP3013946B8 (en) * | 2013-06-28 | 2019-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for expressing a polynucleotide of interest in the retina of a subject |
| GB201403684D0 (en) * | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| GB201519086D0 (en) * | 2015-10-28 | 2015-12-09 | Syncona Partners Llp | Gene Therapy |
| GB201608046D0 (en) * | 2016-05-09 | 2016-06-22 | Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The | Treatment of complement-mediated disorders |
-
2015
- 2015-10-28 GB GBGB1519086.1A patent/GB201519086D0/en not_active Ceased
-
2016
- 2016-10-27 AU AU2016344523A patent/AU2016344523B2/en active Active
- 2016-10-27 DK DK16788764.5T patent/DK3262066T4/da active
- 2016-10-27 PL PL17210269T patent/PL3360890T3/pl unknown
- 2016-10-27 CA CA3002125A patent/CA3002125A1/en active Pending
- 2016-10-27 EP EP17210269.1A patent/EP3360890B1/en active Active
- 2016-10-27 ES ES17210269T patent/ES2828050T3/es active Active
- 2016-10-27 SG SG11201802934WA patent/SG11201802934WA/en unknown
- 2016-10-27 CN CN202311083674.8A patent/CN117343960A/zh active Pending
- 2016-10-27 IL IL304084A patent/IL304084B2/en unknown
- 2016-10-27 US US15/771,849 patent/US20190255193A1/en not_active Abandoned
- 2016-10-27 KR KR1020187015024A patent/KR102922606B1/ko active Active
- 2016-10-27 RU RU2018118954A patent/RU2740038C2/ru active
- 2016-10-27 CN CN202310134734.8A patent/CN116271104A/zh active Pending
- 2016-10-27 MX MX2018005145A patent/MX366343B/es active IP Right Grant
- 2016-10-27 EP EP20187535.8A patent/EP3786176A1/en active Pending
- 2016-10-27 WO PCT/GB2016/053343 patent/WO2017072515A1/en not_active Ceased
- 2016-10-27 CN CN202310132380.3A patent/CN116370655A/zh active Pending
- 2016-10-27 IL IL284577A patent/IL284577B2/en unknown
- 2016-10-27 EP EP16788764.5A patent/EP3262066B2/en active Active
- 2016-10-27 JP JP2018541571A patent/JP7126944B2/ja active Active
- 2016-10-27 CN CN201680073421.4A patent/CN108431030B/zh active Active
- 2016-10-27 NO NO16788764A patent/NO3262066T3/no unknown
- 2016-10-27 HK HK18108313.3A patent/HK1248723B/en active IP Right Maintenance
- 2016-10-27 DK DK17210269.1T patent/DK3360890T3/da active
- 2016-10-27 PL PL16788764.5T patent/PL3262066T5/pl unknown
- 2016-10-27 ES ES16788764T patent/ES2666204T5/es active Active
-
2018
- 2018-04-13 ZA ZA2018/02462A patent/ZA201802462B/en unknown
- 2018-04-18 IL IL258806A patent/IL258806B/en unknown
-
2022
- 2022-05-30 AU AU2022203675A patent/AU2022203675B2/en active Active
- 2022-06-28 JP JP2022103103A patent/JP2022141670A/ja active Pending
- 2022-12-16 US US18/067,283 patent/US20230277689A1/en not_active Abandoned
-
2024
- 2024-07-12 JP JP2024112812A patent/JP2024156706A/ja active Pending
-
2025
- 2025-02-13 AU AU2025200979A patent/AU2025200979A1/en active Pending
- 2025-03-27 US US19/093,102 patent/US20250319210A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022141670A5 (https=) | ||
| JP2021503914A5 (https=) | ||
| JP2018510620A5 (https=) | ||
| JP2018508519A5 (https=) | ||
| TW201629225A (zh) | 第九因子基因療法 | |
| RU2018118954A (ru) | Генная терапия | |
| US11744851B2 (en) | Enhancing AAV-mediated transduction of ocular tissues with hyaluronic acid | |
| US12467066B2 (en) | Compositions and methods for treating retinal disorders | |
| JP2021500922A5 (https=) | ||
| CN113286878A (zh) | 补体因子i和补体因子i辅因子、编码它们的载体和治疗用途 | |
| RU2019103488A (ru) | Способы и композиции для лечения нарушений и заболеваний, связанных с rdh12 | |
| EP4703475A1 (en) | Nucleic acid encoding anti-vegf protein, polynucleotide expression cassette and recombinant adeno-associated virus | |
| IL312657A (en) | Codon-optimised complement factor i | |
| JP7627961B2 (ja) | バルデー・ビードル症候群の遺伝子治療 | |
| JPWO2021084133A5 (https=) | ||
| JPWO2019138250A5 (https=) | ||
| RU2021120124A (ru) | Кодон-оптимизированный фактор комплемента i | |
| JPWO2022079453A5 (https=) | ||
| RU2021119359A (ru) | Фактор комплемента i и кофактор фактора комплемента i, кодирующие их векторы и применение в терапевтических целях | |
| JP2022514271A5 (https=) | ||
| RU2023135479A (ru) | Кодон-оптимизированный фактор комплемента i | |
| Fehrman et al. | The co-transduction conundrum: Improving dual rAAV delivery through co-administration of capsid serotypes with complementary tropism | |
| TW202434733A (zh) | 重組腺相關病毒載體 | |
| JPWO2020236352A5 (https=) | ||
| Karimipoor | Recent Advances in Hemophilia Gene Therapy (STUDY BREAK) |